Evidence map›Paper›PMID 32821877›Full record

ArticleFASEB bioAdvances2020

The regulatory role of PGC1α-related coactivator in response to drug-induced liver injury.

Marcin Buler, Thomas Naessens, Johan Mattsson, Yannick Morias, Magnus Söderberg, Philip Robbins, Lillevi Kärrberg, Tor S Svensson, Petra Thulin, Björn Glinghammar and 2 more

Abstract read
In one paragraph

Article in FASEB bioAdvances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marcin BulerClinical Pharmacology and Safety Sciences AstraZeneca R&D Mölndal Sweden.
Thomas NaessensClinical Pharmacology and Safety Sciences AstraZeneca R&D Mölndal Sweden.
Johan MattssonClinical Pharmacology and Safety Sciences AstraZeneca R&D Mölndal Sweden.
Yannick MoriasClinical Pharmacology and Safety Sciences AstraZeneca R&D Mölndal Sweden.
Magnus SöderbergClinical Pharmacology and Safety Sciences AstraZeneca R&D Mölndal Sweden.
Philip RobbinsCitizen Scientist Bruce ACT Australia.
Lillevi KärrbergClinical Pharmacology and Safety Sciences AstraZeneca R&D Mölndal Sweden.
Tor S SvenssonClinical Pharmacology and Safety Sciences AstraZeneca R&D Mölndal Sweden.
Petra ThulinClinical Pharmacology and Safety Sciences AstraZeneca R&D Mölndal Sweden.
Björn GlinghammarScience for Life Laboratory Drug Discovery & Development Platform & Division of Translational Medicine & Chemical Biology Department of Medical Biochemistry and Biophysics Karolinska Institutet Stockholm Sweden.
Richard C ScarpullaDepartment of Cell and Molecular Biology Northwestern Medical School Chicago IL USA.
Ulf AnderssonClinical Pharmacology and Safety Sciences AstraZeneca R&D Mölndal Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PGC1α-Related Coactivator (PRC) is a transcriptional coactivator promoting cytokine expression in vitro in response to mitochondrial injury and oxidative stress, however, its physiological role has remained elusive. Herein we investigate aspects of the immune response function of PRC, first in an in vivo thioacetamide (TAA)-induced mouse model of drug-induced liver injury (DILI), and subsequently in vitro in human monocytes, HepG2, and dendritic (DC) cells. TAA treatment resulted in the dose-dependent induction of PRC mRNA and protein, both of which were shown to correlate with liver injury markers. Conversely, an adenovirus-mediated knockdown of PRC attenuated this response, thereby reducing hepatic cytokine mRNA expression and monocyte infiltration. Subsequent in vitro studies with conditioned media from HepG2 cells overexpressing PRC, activated human monocytes and monocyte-derived DC, demonstrated up to 20% elevated expression of CD86, CD40, and HLA-DR. Similarly, siRNA-mediated knockdown of PRC abolished this response in oligomycin stressed HepG2 cells. A putative mechanism was suggested by the co-immunoprecipitation of Signal Transducer and Activator of Transcription 1 (STAT1) with PRC, and induction of a STAT-dependent reporter. Furthermore, PRC co-activated an NF-κB-dependent reporter, indicating interaction with known major inflammatory factors. In summary, our study indicates PRC as a novel factor modulating inflammation in DILI.

Indexed as

cytokine expressiondrug‐induced liver injuryhepatic inflammationPPRC1PRC

Identifiers

PMID32821877
PMCPMC7429352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.